Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 177 across all filing types
Latest filing 2019-03-11 Proxy Solicitation & In…
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Optipharm. It outlines the date, location, agenda items (including financial statement approval, director appointments, and remuneration limits), and details regarding the board's resolution. This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2019-03-11 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Optipharm, detailing the meeting date, location, agenda items (financial statements, board changes, etc.), and management information. This document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and solicit their participation. In the context of the provided categories, this aligns with 'Proxy Solicitation & Information Statement' (PSI).
2019-03-11 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory notice regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming general meeting. It does not contain full financial statements or proxy materials, but rather serves as a formal regulatory announcement of a corporate action. Given it does not fit into specific categories like dividend announcements or share buybacks, it falls under the general regulatory filing category.
2018-12-31 Korean
기업설명회(IR)개최
Investor Presentation Classification · 1% confidence The document is a formal announcement regarding the scheduling and details of an Investor Relations (IR) event (Corporate Day). It specifies the date, location, purpose, and agenda for the meeting. Since it is an announcement of an upcoming presentation rather than the presentation slides themselves, and it fits the criteria for a regulatory notification of an event, it is classified as a Regulatory Filing (RNS).
2018-11-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is the standard Korean regulatory filing for disclosing significant ownership stakes (often referred to as the 5% rule). It details the shareholding status of the company (Optipharm) and its special related parties (Easy Bio and others) following a new listing on the KOSDAQ. This falls under the 'Major Shareholding Notification' category.
2018-11-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used to disclose changes in shareholdings by insiders or major shareholders. This falls under the category of 'Major Shareholding Notification' (MRQ) as it details the ownership status and changes in shareholdings of a major shareholder (Easy Bio) in the issuing company (Optipharm).
2018-11-02 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.